We are live on ! Find out more
DMAAR

Drugs Made In America Acquisition Corp Rights
DMAAR

19 hedge funds and large institutions have $2.53M invested in Drugs Made In America Acquisition Corp Rights in 2025 Q1 according to their latest regulatory filings, with 19 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
19
Holders Change
+19
Holders Change %
–
% of All Funds
0.25%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
19
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
PAMP
Polar Asset Management Partners
Ontario, Canada
+$267K
2
Hudson Bay Capital Management
Hudson Bay Capital Management
Connecticut
+$253K
3
HCI
Harraden Circle Investments
New York
+$211K
4
GCL
Glazer Capital LLC
New York
+$183K
5
AC
Aristeia Capital
Connecticut
+$126K

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
CA
1
Crossingbridge Advisors
New York
$807K +$119K +850,000 New
PAMP
2
Polar Asset Management Partners
Ontario, Canada
$247K +$267K +1,900,000 New
Hudson Bay Capital Management
3
Hudson Bay Capital Management
Connecticut
$234K +$253K +1,800,000 New
HCI
4
Harraden Circle Investments
New York
$195K +$211K +1,500,000 New
GCL
5
Glazer Capital LLC
New York
$169K +$183K +1,300,000 New
AC
6
Aristeia Capital
Connecticut
$117K +$126K +900,000 New
HCM
7
Highbridge Capital Management
New York
$111K +$119K +850,000 New
MP
8
Mangrove Partners
Connecticut
$111K +$119K +850,000 New
WAM
9
Wolverine Asset Management
Illinois
$78.4K +$84.7K +603,038 New
ASM
10
ATW SPAC Management
New York
$74.1K +$80K +570,000 New
CS
11
Clear Street
New York
$71.5K +$77.2K +550,176 New
AA
12
AQR Arbitrage
Connecticut
$65K +$70.2K +500,000 New
CF
13
Cantor Fitzgerald
New York
$65K +$70.2K +500,000 New
LP
14
LMR Partners
United Kingdom
$65K +$70.2K +500,000 New
WA
15
Whitebox Advisors
Minnesota
$52K +$56.2K +400,000 New
SSA
16
Schonfeld Strategic Advisors
New York
$26K +$28.1K +200,000 New
MSU
17
Mizuho Securities USA
New York
$21K +$29.5K +209,897 New
QL
18
Quarry LP
New York
$19.5K +$21.1K +150,000 New
WAM
19
Warberg Asset Management
Illinois
$2.4K +$2.59K +18,443 New

DMAAR Hedge Fund Activity: Q1 2025 in Review

19 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Drugs Made In America Acquisition Corp Rights (DMAAR) for Q1 2025, worth a combined $2.53M.

Buyers outnumbered sellers: 19 funds opened new DMAAR positions and 0 closed out — a net gain of 19 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Polar Asset Management Partners, opening a new position worth an estimated $267K.

  • 19 institutional investors held Drugs Made In America Acquisition Corp Rights (DMAAR) as of Q1 2025, up from 0 in Q4 2024.
  • Funds reported $2.53M of Drugs Made In America Acquisition Corp Rights stock for Q1 2025.
  • 19 funds opened new Drugs Made In America Acquisition Corp Rights positions in Q1 2025 and 0 closed out, a net change of +19 holders.
  • The largest Drugs Made In America Acquisition Corp Rights buyer in Q1 2025 was Polar Asset Management Partners, an estimated $267K added.

Based on aggregated 13F filings for Q1 2025.